serogroup B meningococcal vaccine

BIOLOGICAL2 trials

Sponsors

Novartis Vaccines, Novartis

Conditions

Meningococcal DiseaseMeningococcal Meningitis

Phase 2

Study of the Safety and Immune Response of Two Serogroup B Meningococcal Vaccines Administered to Healthy Adolescents

CompletedNCT00297817

Novartis VaccinesMeningococcal Disease

Start: 2006-02-28End: 2007-04-30Updated: 2016-12-01

Phase 3

Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years

CompletedNCT01423084

NovartisMeningococcal Disease, Meningococcal Meningitis

Start: 2011-08-31End: 2011-12-31Updated: 2015-02-20

Related Papers

152. Protective Antibody Levels 7.5 Years After Primary Vaccination in Adolescence With a Recombinant, 4-Component, Meningococcal Serogroup B Vaccine (4CMenB) and Response to a Booster Dose in Adolescents and Young Adults: Phase IIIb Clinical Findings

Open Forum Infectious Diseases2018-11-011 citations

Persistence of Bactericidal Activity at 4 Years After 2 Primary Doses of a Recombinant, 4-Component, Meningococcal Serogroup B Vaccine (4CMenB) and Response to a Booster Dose in Adolescents and Young Adults

Open Forum Infectious Diseases2017-01-013 citations

Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: a phase III, randomized, multicentre, lot-to-lot consistency study.

2015-07-2936 citations